Our Science

ZEUS: Zebrafish for Epilepsy DrUg Selection

ZEUS is the first zebrafish-based drug discovery platform designed specifically for genetic epilepsies. ZEUS uses gene editing to create zebrafish models that faithfully recapitulate genetic epilepsies. Using these models, a phenotype-based screening system systematically identifies the most promising drug candidates. This platform was developed at UCSF and identified the candidates licensed by Epygenix

Fish Graphic

(1) Zebrafish are genetically edited to model rare genetic epilepsies. For example, generating the loss-of-function SCN1A mutation seen in over 80% of Dravet Syndrome patients

(2) Models undergo rigorous multi-modal validation, including molecular, phenotypic, and pharmacologic evaluations

(3) EPX candidates are identified in blinded screenings of thousands of candidates in a zebrafish model using multiple phenotypic assays: locomotion, electrophysiology, and toxicity

Highly Translatable

The zebrafish model faithfully mimics human epilepsy phenotypes & is pharmacologically validated against multiple AEDs

Validated Candidates

Drug candidates can be repurposed drugs & are screened through multiple layers of phenotype-based assays

Rapid

Zebrafishes’ rapid reproductive cycle enable high-throughput screening of thousands of drug candidates

Multi-Indication

Platform can be expanded to most refractory, genetically-related epilepsies, which represents ~20% of epilepsy patients

Breadth of Impact

The ZEUS platform and its discovered EPX candidates have been validated in multiple genetic epilepsies. These include scn1lab zebrafish of Dravet Syndrome as well as models of other genetic epilepsies. Looking ahead, ZEUS has the potential to expand into additional genetic epilepsy indications as well.

DISCLOSURE: THE ZEBRAFISH PLATFORM WAS DEVELOPED IN THE BARABAN LABORATORY AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF). EPYGENIX HAS LICENSED SPECIFIC DRUG CANDIDATES AND INTELLECTUAL PROPERTY DISCOVERED BY THE AFOREMENTIONED PLATFORM AT UCSF.

To Learn More